摘要
目的探讨分析武汉地区经皮冠状动脉介入治疗(PCI)术后需口服抗血小板药物治疗的冠心病患者CYP2C19基因多态性的分布情况,以指导临床抗血小板药物的使用。方法收集2015年8月~2016年8月武汉市武昌医院心内科行PCI术后、需服用氯吡格雷进行抗血小板治疗的冠心病汉族患者186例,用PCR荧光法对该类患者CYP2C19基因进行检测,计算基因多态性分布的频率,比较不同性别基因多态性的区别。结果男性109例患者中,CYP2C19*2野生型为51例(46.79%),突变杂合型44例(40.37%),突变纯合型14例(12.84%),CYP2C19*3野生型为103例(94.49%),突变杂合型6例(5.51%),无突变纯合型。女性77例患者,CYP2C19*2野生型为38例(49.35%),突变杂合型30例(38.96%),突变纯合型9例(11.69%);CYP2C19*3野生型为74例(96.10%),突变杂合型3例(3.90%),无突变纯合型。结论该地区男女基因多态性分布频率无显著性差异。
Objective To explore the Wuhan area PCI（ percutaneous coronary intervention） in patients with coronary heart disease CYP2C19 genepolymorphism distribution after oral antiplatelet drug therapy, to guide clinical use of antiplatelet drugs. Methods From August 2015 to August 2016 in186 patients with coronary heart disease in the Wuhan city Wuchang Hospital Department of Cardiology after PCI, clopidogrel antiplatelet therapy patients,to detect the CYP2C19 gene with PCR fluorescence method, calculate the frequency of gene polymorphism, and compare the differences between genepolymorphism in different gender gene. Results 109 cases of male patients with wild type CYP2C19＊2 51 cases, heterozygous mutation in 44 cases,homozygous mutation in 14 cases of wild type ;CYP2C19＊3 103 cases, heterozygous mutation 6 cases, no homozygous mutation. 77 cases of female patientswith wild-type CYP2C19＊2 38 cases, heterozygous mutation in 30 cases, homozygous mutation in 9 cases; the wild type CYP2C19＊3 74 cases heterozygousmutation 3 cases Conclusion There is no significant difference in the frequency and gene polymorphism in the region.
出处
《中国处方药》
2018年第1期1-2,共2页
Journal of China Prescription Drug
